Introduction
Although the molecular and cytogenetic characterization of canine cancers lags behind that of human malignancies, the recent identi®cation of canine protooncogenes and tumour suppressor genes suggests that the mechanisms of tumorigenesis may be similar between species. An obvious candidate for mutation in canine cancer is the p53 gene which is highly conserved between species and is the most commonly aected gene in human cancer (for a recent review see Hainaut et al., 1997) .
p53 is a tumour suppressor protein and plays an important role in cell growth control and in the maintenance of genomic integrity (reviewed in Ko and Prives, 1996) . In the dog, mutations of the p53 gene have already been identi®ed in the following malignancies: thyroid carcinoma (Devilee et al., 1994) , oral papilloma (Mayr et al., 1994) , mammary tumours (Van Leeuwen et al., 1996) , and osteosarcoma (Van Leeuwen et al., 1997) . However, the status of the p53 gene in canine lymphoma is unknown. Lymphoma represents 6% of canine malignant cancers (MacVean et al., 1978) . It is clinically and morphologically similar to human non Hodgkin's lymphoma and may represent an attractive clinical model for investigations of cancer treatment and prevention (Carter et al., 1986; Greenlee et al., 1990) .
The present study investigates the status of the p53 gene in normal and tumour tissue from eight canine patients treated for primary and secondary lymphoma. An association of de novo p53 mutations was observed with the chemoresistant secondary lymphomas of two patients and we propose that the dog may provide a good clinical model for development of more eective chemotherapeutic programs with a reduced risk of p53 mutagenesis. In addition, one patient displayed a mutant p53 gene within normal tissue. This is the ®rst evidence for germ line mutations of the p53 gene in the dog and its implications are discussed.
Results

Clinical features of the canine patients
The clinical information for each patient is shown in Table 1 . The primary lymphomas of patients 4 and 5 were classi®ed as T-cell in origin based on the presence of TCR b chain rearrangements. The primary tumours of the remaining six patients were classi®ed as B-cell lymphomas. The level of P-glycoprotein expression was determined in normal liver and tumour tissue samples from each canine patient by immunohistochemical staining. A minimum of two independent tissue samples were stained and those with over 80% Pglycoprotein positive cells were scored as positive (Table 1) . Only two out of eight lymphomas were positive for P-glycoprotein expression (patients 7 and 8) and interestingly, neither responded to treatment. Patient 8 showed a therapy-related increase in Pglycoprotein expression, whereas patient 7 displayed increased levels of P-glycoprotein before and after chemotherapy (Table 1) .
DNA sequencing of the p53 gene
To determine whether p53 gene mutations are associated with canine lymphomas, exons encoding the central core domain of p53 were examined in eight canine patients. It should be noted that the entire coding sequence of the canine p53 gene is as yet unknown. Genomic DNA samples were obtained from normal tissue and primary lymphoma at initial diagnosis and from secondary lymphoma following chemotherapy treatment. Primers used in the amplification and analysis of canine p53 DNA are shown in Table 2 and were designed based on partial cDNA sequence information from Kraegel et al. (1995) and from our own sequencing of canine genomic DNA. Mutations within the p53 gene were identi®ed in three of the eight canine patients analysed (Figures 1 and 3 ). For clarity, these mutations will be referred to using the equivalent exon nomenclature and amino acid codon positions within the human p53 gene as described by Soussi et al. (1990) .
Unexpectedly, patient 1 proved to be heterozygous for p53 in both normal and tumour samples (Figures 1  and 2 ). This ®nding was con®rmed in both liver and peripheral blood lymphocyte DNA samples. The presence of a p53 mutation in normal tissue indicates that the mutation was inherited through the germ line and this is the ®rst identi®cation of a germ line p53 mutation in the dog. Individual clones containing the wild type allele and the germ line mutant allele are shown separately in Figure 1 . The mutant allele contained a two base pair insertion within exon 7, resulting in a frameshift mutation at codon 234 and incorporation of a stop codon at position 247. Previous studies have indicated that introduction of a stop codon within the core domain of p53 is sucient to abolish expression of the p53 protein (Harvey and Levine, 1991) . The presence of a single functional wild type p53 allele within the germ line could have resulted in a predisposition to cancer for patient 1. In this patient, the primary lymphoma contained only the wild type p53 allele with loss of the mutant allele (Figure 2) .
Analysis of the secondary lymphoma in this dog revealed the presence of both wild type and mutant p53 alleles (Figure 2 ). This indicates that the primary and secondary lymphomas of patient 1 were not clonally related.
Patient 2 displayed wild type p53 sequence in both normal tissue and in the primary lymphoma. In the secondary lymphoma, a single base transition mutation was observed within exon 6 of the p53 gene (Figure 3 , white arrowhead). This mutation results in a codon change from GTG to ATG and a predicted amino acid substitution of valine to methionine at position 216 (see Figure 4 ). Patient 3 also contained wild type p53 in both normal tissue and primary lymphoma. The p53 gene within the secondary lymphoma contained a single base transition mutation in exon 6 (Figure 3 , black arrowhead). The codon change from CGA to TGA results in the incorporation of a stop codon at position 213 (see Figure 4) . No wild type p53 sequence was detectable within the secondary lymphomas of either patient 2 or 3 suggesting that the second p53 allele had been lost within these tumours.
Allelic loss of the p53 gene
In a variety of human cancers, point mutation within one p53 allele is associated with a complete loss of the second p53 allele (see Hainaut et al., 1997) . In the present study we asked if a similar situation occurs 
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Ile 232 His 233 Tyr 234 Aps 235 Figure 1 Characterization of a p53 mutation in patient 1. Both wild type and mutant p53 alleles isolated from the secondary lymphoma are shown. A two base pair insertion at codon 234 in exon 7 of the mutant allele is denoted by boldface Figure 5 and are summarized for all patients in Table 3 . The p53 gene from normal DNA of patient 3 competed eectively for p53-speci®c ampli®cation compared with the cDNA internal control (see Figure 5 , normal tissue). However, a reduction in ampli®cation of the genomic p53 DNA fragment within the primary and secondary lymphomas of patient 3 ( Figure 5 ) indicates that p53 allelic loss has occurred in both tumours. Similar analyses showed p53 allelic loss in the secondary lymphoma of patient 2 and in the primary lymphoma of patient 1 (Table 3) . The remaining ®ve patients displayed no change in the allelic status of the p53 gene.
Determination of tumour cell clonality
Tumour cells harbouring a mutant p53 gene may be clonally ampli®ed during disease progression or, alternatively, arise in response to exposure to DNAdamaging chemotherapy (Ahuja et al., 1989; Sidransky et al., 1992) . In order to determine whether the p53 mutations present in the secondary lymphomas of patients 1, 2 and 3 arose de novo or from a population of cells present in the primary tumour we performed a mutant-speci®c DNA ampli®cation assay. This technique is very sensitive and is able to detect p53 mutations which represent as little as 2% of the genomic DNA sample (data not shown). Thus, by screening normal and tumour samples for mutant alleles of p53 identi®ed in the secondary lymphomas (see Figure 4 ) we aimed to clarify the clonal origin of these mutations. The results for each mutant-speci®c DNA ampli®cation assay are shown in Figure 6 . As expected from the sequence analyses, patient 1 displayed both wild type and mutant p53 DNA ampli®ed from normal tissue and from secondary lymphoma genomic DNA (Figure 6, lanes N and S) . In this dog the primary lymphoma contained only wild Figure 6 , lane P) con®rming our sequencing data which showed that the primary tumour had lost the p53 allele containing the germ line mutation (see Figure 2) . The dierence in allelic status combined with results of the mutant-speci®c DNA ampli®cation analysis con®rm separate clonal origins for the primary and secondary lymphomas in patient 1. The sequencing data for patients 2 and 3 revealed p53 mutations in the secondary lymphomas but the primary tumours appeared to be wild type for p53.
Using the highly sensitive mutant-speci®c DNA ampli®cation assay we were unable to detect any evidence of the relevant mutations in the primary lymphomas of each dog. This strongly suggests that the mutations in p53 arose after initial diagnosis of the primary lymphoma had occurred and during chemotherapy.
Discussion
Our results demonstrate that mutation of the p53 gene occurs in lymphoma of the dog. Two out of eight patients displayed tumour-derived mutant p53 genes, while a third contained a germ line p53 mutation (Figure 7 ). To our knowledge this represents the ®rst example of a germ line mutation of the p53 gene in dogs. Importantly, the dog concerned was a Bull Masti and this breed has been shown to exhibit a high incidence of familial lymphoma (Onions, 1984) . Thus some canine families may exist with inheritable mutant p53 genes that confer a predisposition to cancer. A similar situation is already well documented for humans, as exempli®ed by the Li-Fraumeni syndrome (LFS) in which families exhibit germ line mutation of the p53 gene (for a recent review see Malkin, 1994) . Individuals carrying the germ line mutation show increased susceptibility to various tumour types (Frebourg et al., 1992 (Frebourg et al., , 1995 . Our present results indicate that germ line mutations in p53 may also play a role in canine cancer and might explain the predisposition of certain breeds to develop cancer. This predisposition to cancer within LFS families is associated with an increase in chromosomal instability (Liu et al., 1996) . Loss of chromosomal stability may also apply to the dog containing a germ line p53 mutation since we show that the mutant p53 allele was lost in the primary canine lymphoma. Only the remaining wild type allele was detectable ( Figure 6 ; patient 1). An equivalent situation has also been reported for Li-Fraumeni patients, where loss of the mutant germ line allele and retention of the wild type p53 allele was evident in liposarcoma and in adrenocortical carcinoma (Varley et al., 1997) .
Two of the dogs (patients 2 and 3) were shown to have de novo mutations of the p53 gene within their secondary lymphomas (summarized in Figure 7 ). Both Retention of a normal level of p53 alleles is denoted by a`+' symbol, while`7' identi®es genomic samples with a reduction in the amount of p53 DNA
Mutations of the p53 gene in canine lymphoma N Veldhoen et al dogs were treated with an epirubicin-based chemotherapy for approximately 1 year prior to tumour relapse. In humans, many therapy-related secondary tumours are associated with allelic loss or de novo point mutation of the p53 gene (Pedersen-Bjergaard, 1990; Chang et al., 1994; Hsiao et al., 1994; Kurosawa et al., 1994; Aas et al., 1996; Felix et al., 1996) . Such mutations are important since they often appear to confer resistance to further anti-cancer treatment (Lowe et al., 1994; Wada et al., 1994; Aas et al., 1996) . Loss or translocation of chromosomal material has been observed in the secondary tumours of human patients treated with epirubicin or the closely related drug doxorubicin (Pedersen-Bjergaard et al., 1992; Homann et al., 1995) . This type of genetic damage is suggested to result from intercalation of the drug into DNA and inhibition of DNA topoisomerase II activity (Tewey et al., 1984; Bartkowiak et al., 1992) . However, the mechanism by which epirubicin may induce single point mutations within DNA is not clear. Anthracycline drugs, such as epirubicin, exhibit strong redox cycling properties within the cell and can generate a signi®cant amount of DNA-damaging hydroxyl radicals (Kappus, 1986; Cervantes et al., 1988; Keizer et al., 1990; Turner III et al., 1990; Doroshow, 1996) . The mutations observed at GC base pairs within the p53 genes of both patients 2 and 3 would be consistent with a mechanism involving radical ion attack of guanine or cytosine DNA base residues (Muindi et al., 1985; McBride et al., 1991; Akman et al., 1992) . Long term exposure to epirubicin could select for canine lymphoma cells containing therapy-induced p53 gene mutations and displaying a chemoresistant phenotype.
Canine lymphomas resistant to anti-cancer drugs can also arise from an increase in the expression of the multi-drug resistance (mdr) gene family (Lee et al., 1996) . Here we show that the lack of tumour response to chemotherapy treatment for patients 7 and 8 is associated with an elevated level of Pglycoprotein (Table 1) . However, none of the canine patients with p53 mutations in primary or secondary lymphomas displayed a change in P-glycoprotein expression. The lack of correlation between p53 gene mutation and upregulation of P-glycoprotein expression has also been observed in human haematopoietic malignancies (el Rouby et al., 1993; Preudhomme et al., 1993) .
In summary, we present evidence for de novo mutations and allelic loss of the p53 gene associated with secondary lymphoma of the dog. These genetic aberrations are linked with long term administration of anti-tumour drugs known to induce DNA damage and which may thus help to select for tumorigenic clones with an increased chemoresistant phenotype. The presence of a germ line mutation in the p53 gene of one patient suggests that the canine equivalent of Li-Fraumeni syndrome may exist. We believe that canine lymphoma and the status of the canine p53 gene provides a valuable clinical model to investigate the ecacy of various combination chemotherapy regimens as well as their tumorigenic potential. The development of anti-cancer therapies that do not damage genomic DNA may also bene®t from studies of canine cancer.
Materials and methods
Plasmids and bacterial strains
Ampli®ed canine p53 gene fragments were cloned into the plasmid pTZRJL1. Plasmid cp53core contained the central region of the canine cDNA cloned into pTZRJL2. All plasmid constructs were maintained in E. coli XL-1 Blue MRF'.
Clinical parameters
Classi®cation of canine lymphomas are based on Squires et al. (1973) . All patients presented with stage III lymphosarcoma characterized by a general involvement of lymphoid tissue (e.g. nodes, spleen, tonsils, and thymus). Clinical features of the disease were divided into`A' denoting slight systemic signs and`B' denoting severe systemic signs. Lymphoid genotype was determined by analysis of TCR b chain rearrangements. Complete remission of the primary lymphoma was de®ned as the absence of clinical signs of disease from the time of chemotherapy induction until detection of one or more enlarged lymph nodes either clinically or radiographically.
Lymphoid genotyping
Canine lymphoma samples were genotyped by Southern blot analysis of TCR b chain rearrangements. The probe DNA consisted of the virally transduced feline TCR b chain region obtained from a feline T17 genomic library (Fulton et al., 1987) . A 390 bp restriction DNA fragment containing the TCR b chain was labelled using a 32 P-(dCTP) and the Prim-it random primer kit as per the manufacturers protocol (Stratagene). Normal and lymphoma genomic DNA samples (20 mg) were prepared for Southern blotting essentially as described by Southern (1975) . DNA samples were digested with EcoRI, KpnI, XbaI, or HindIII and electrophoresed on a 1% agarose gel overnight at 40 mA. Separated DNA was alkaline denatured and transferred onto Genescreen membranes as per the manufacturers protocol (New England Nuclear). Membranes containing transferred DNA were subsequently baked at 808C for 2 h. Hybridizations with the radiolabeled TCR DNA probe were performed in a buer containing 50 mM Pipes, 100 mM NaCl, 50 mM Na 2 HPO 4 , 50 mM NaH 2 PO 4 , 1 mM EDTA, and 5% SDS. Membranes were hybridized at 658C for 16 h in a Hybaid oven (Hybaid Ltd.) and then washed ®ve times in wash buer (150 mM NaCl, 15 mM tri-sodium citrate, and 5% SDS). Hybridized ®lters were exposed to Kodak AR ®lm at 7708C with intensifying screens. TCR b chain rearrangements were identi®ed by changes in the hybridization patterns of lymphoma samples compared with germ line DNA samples.
Chemotherapy protocols
Patients received one of the following chemotherapy protocols. Treatment was maintained until relapse occurred. Chemotherapy: (1) EP protocol; epirubicin-25 mg/m 2 intravenously, every 3 weeks until relapse; prednisolone-2 mg/kg orally, daily for 7 days; 1 mg/kg, daily for seven days; 1 mg/kg, every other day until relapse; (2) COP protocol; cyclophosphamide-2.2 mg/kg orally, 3 days a week; vincristine-0.022 mg/kg, weekly; prednisilone-2.2 mg/kg orally, daily for 7 days; 1.1 mg/kg, daily until relapse.
Tissue isolation and genomic DNA preparation
Lymphomatous nodes were obtained from surgical biopsies of primary lymphomas at patient presentation and from secondary lymphomas at time of death. Normal tissue samples were obtained from the liver (patient 1), the kidney (patients 5, 6, 7, and 8), or from peripheral blood lymphocytes (patients 1, 2, 3, and 4) at time of death. Genomic DNA was prepared from tissue samples based on the methods described by Gross-Bellard et al. (1973) . Blood samples (8 ml) were prepared for DNA extraction by ®rst lysing red blood cells and collecting white blood cells by centrifugation at 1500 g for 10 min. Protein contaminants were removed from tissue and white blood cell preparations by phenol-chloroform-isoamyl alcohol (25 : 24 : 1) extraction. Genomic DNA was precipitated with an equal volume of isopropanol at 48C for 1 h and pelleted by centrifugation. DNA pellets were air dried and resuspended in distilled water.
Canine p53 gene ampli®cation and analysis
Exons encoding the central core domain of canine p53 were ampli®ed by nested PCR. The 50 ml primary ampli®cation reaction contained 10 mM Tris-HCl (pH 8.85 at 208C), 25 mM KCl, 5 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 100 mM dNTPs (dATP, dCTP, dGTP, dTTP), 0.25 mM primer 4 up, 0.25 mM primer 8dn, 5 mg genomic DNA, and 2.5 units Pwo DNA polymerase (Boehringer). The thermocycle program included a denaturation step at 948C (7 min), 25 cycles of 948C (60 s), 558C (60 s) and 728C (3 min) and a ®nal elongation step at 728C (7 min). The 100 ml secondary ampli®cation reaction was similar to the primary reaction with the exception of the following modi®cations. Genomic DNA was replaced by 2 ml of the primary ampli®cation reaction, the dNTP concentration was reduced to 75 mM and the Pwo DNA polymerase was reduced to 1.25 units per reaction. Primer sets for the secondary ampli®cation included 5up/6dn and 7up/8dn. The thermocycle program included a denaturation step at 948C (7 min), 30 cycles of 948C (60 s), 558C (60 s) and 728C (60 s) and a ®nal elongation step at 728C (7 min).
The completed secondary ampli®cation reactions were phenol extracted, ethanol precipitated, and resuspended in a 20 ml restriction reaction containing 10 mM Tris-HCl (pH 7.5 at 378C), 10 mM MgCl 2 , 100 mg/ml BSA, 8 units KpnI and 8 units BamHI. Restriction reactions were incubated for 2 h at 378C and run on a 1.5% agarose gel. Gel slices containing cut DNA fragments were excised and spun for 5 min in microspin columns (Pharmacia). Puri®ed DNA fragments containing canine p53 gene sequence were subsequently cloned into the KpnI and BamHI sites of pTZRJL1 and transformed into E. coli XL-1 Blue MRF'. Individual plasmid clones were isolated by alkaline-SDS mini preparation (IGi). Positive clones were identi®ed by restriction analysis and PCR ampli®cation. Six clones of each sample were combined for DNA sequencing (Pharmacia).
RT ± PCR isolation of canine p53 cDNA
The central region of the p53 cDNA was isolated and cloned from the peripheral blood leukocytes (PBL) of a healthy dog. A 30 ml mRNA preparation was isolated from 1.2610 9 PBL cells using the PolyATract System 1000 kit as per the manufacturers protocol (Promega). Canine p53 cDNA was prepared by reverse transcriptase-PCR using the Access RT ± PCR kit as per the manufacturers protocol (Promega). The reverse transcriptase-PCR reaction included 3 ml of canine mRNA and the primers 3up and 8dn. The cDNA products were cut with BamHI and puri®ed by agarose gel electrophoresis and Geneclean (Bio 101). Puri®ed cDNA fragments were ligated into plasmid pTZRJL2 and transformed into E. coli XL-1 Blue. The positive clone, cp53core, containing the central sequence of canine p53 cDNA was identi®ed by restriction analysis and DNA sequencing.
